A61K 31/5685
Having an oxo group in position 17
Official title: having an oxo group in position 17, e.g. androsterone
A61K31/5685 (Having an oxo group in position 17) appears on 261 US grants and 524 published applications in this corpus.
Search patents in A61K- Granted patents
- 261
- Published applications
- 524
- Assignees
- 232
- Inventors
- 714
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 4 | 0 |
| 1998 | 16 | 0 |
| 1999 | 12 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 3 |
| 2002 | 11 | 11 |
| 2003 | 9 | 26 |
| 2004 | 1 | 31 |
| 2005 | 2 | 27 |
| 2006 | 0 | 12 |
| 2007 | 2 | 12 |
| 2008 | 2 | 11 |
| 2009 | 4 | 13 |
| 2010 | 8 | 21 |
| 2011 | 5 | 16 |
| 2012 | 8 | 22 |
| 2013 | 13 | 25 |
| 2014 | 9 | 31 |
| 2015 | 10 | 27 |
| 2016 | 13 | 13 |
| 2017 | 12 | 28 |
| 2018 | 8 | 23 |
| 2019 | 18 | 20 |
| 2020 | 15 | 28 |
| 2021 | 15 | 30 |
| 2022 | 4 | 21 |
| 2023 | 14 | 28 |
| 2024 | 8 | 20 |
| 2025 | 12 | 14 |
| 2026 | 10 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method and composition for an improved bioavailability delivery system1 Sep 2026US 12,721,814 B2Americana Pharma LLC
- Sulfated C19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases11 Aug 2026US 12,702,673 B2Universidad Pablo De Olavide
- Intravenous istaroxime for the treatment of acute heart failure4 Aug 2026US 12,697,343 B2Seismic Pharmaceuticals Operations LLC
- Pharmaceutical use14 Apr 2026US 12,599,612 B2Lucolas-M.D. Ltd.
- Pharmaceuticals and dosing means for human aging reversal14 Apr 2026US 12,599,651 B2Intervene Immune Inc.
- Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof24 Sep 2026US 2026/0285879 A1CSPC Ouyi Pharmaceutical Co., Ltd
- Istaroxime-Containing Intravenous Formulation for the Treatment of Pre-Cardiogenic Shock and Cardiogenic Shock3 Sep 2026US 2026/0256808 A1Windtree Therapeutics, Inc.
- Methods of treating pancreatic cancer27 Aug 2026US 2026/0250684 A1The Regents of the University of California
- Methods for determining drug candidates20 Aug 2026US 2026/0245655 A1Mosaiques Diagnostics and Therapeutics AG
- Lasofoxifene treatment of aromatase-resistant er+ cancer23 Jul 2026US 2026/0207550 A1Sermonix Pharmaceuticals, Inc.
Most cited
By later US patents
- Transdermal delivery of dehydroepiandrosterone103US 5,869,090 A1999
- Pharmaceutical composition and method for treating hypogonadism101US 6,503,894 B1Laboratories Besins Iscovesco · 2003
- Use of androgen therapy in fibromyalgia and chronic fatigue syndrome82US 5,935,949 ATrustees of Dartmouth College · 1999
- Administration of non-oral androgenic steroids to women78US 6,583,129 B1Watson Pharmaceuticals, Inc. · 2003
- Apparatus and method for delivering compounds to a living organism77US 6,471,979 B2Estrogen Vascular Technology, LLC · 2002